Louis M. Staudt, M.D., Ph.D., deputy chief of NCI’s Metabolism Branch in the Center for Cancer Research, has recently been elected into The National Academy of Sciences. The NAS is a private, non-profit society, established in 1863 by Congress. It serves as an objective science and technology resource for the nation.
Members include experts in the scientific, engineering, and health professional fields, all of whom volunteer their time to provide reports that have significantly improved the welfare of citizens worldwide.
Staudt is just one of the 84 new members who were nominated by peers, in recognition of their notable and ongoing achievements in original research. All newly appointed members will be officially inducted into the NAS during an April 2014 ceremony.
Staudt is known as a pioneer of gene expression profiling His laboratory currently studies the molecular basis of human lymphoid malignancies through the use of functional genomics, chemical genetics and molecular biological techniques. His groundbreaking developments in cancer research and genomics include the discovery of previously unknown types of diffuse large B cell lymphoma, the use of gene expression profiling to identify distinct cancer subgroups, the prediction of cancer patient survival with the use of gene expression signatures, and the discovery of new therapeutic targets in molecularly-defined subtypes of cancer using loss-of-function RNA interference (RNAi) genetic screens.
“This nomination is very gratifying because it validates some of the ideas about lymphoma diagnosis and treatment that we have been trying to promote over the past decade,” Staudt said. “It establishes that we are on a path of making progress for patients. Also, it is a true testament to the strong support given to our lab by the NCI and especially to the outstanding post docs, students, and technicians working in the lab over the past 25 years.”
In this video from March 2012, Staudt discusses the basic biology of targeted therapy for Diffuse B-cell Lymphoma and about ibrutinib, a drug with a high degree of efficacy—and only modest side effects—in the treatment of the ABC form of Diffuse B-cell Lymphoma.